openPR Logo
Press release

Global Orphan Drugs Market Research Report 2023

10-09-2023 07:18 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Valuates Reports

The global Orphan Drugs market was valued at USD 153130 million in 2022 and is anticipated to reach USD 269210 million by 2029, witnessing a CAGR of 9.9% during the forecast period 2023-2029.

Because of favorable government laws and a rise in the prevalence of rare diseases, the market for orphan drugs is growing.

Increasing R&D efforts will aid the growth of the orphan medication industry globally. Due to the significant development potential in undeveloped emerging nations and the rise in new indications for well-known orphan drugs, market expansion is predicted to be lucrative throughout the projection period.

VIEW FULL REPORT
https://reports.valuates.com/reports/QYRE-Auto-29S2943/global-orphan-drugs

Orphan Drugs Market Trends
Orphan pharmaceuticals are prescription medications that are used to diagnose and treat rare medical disorders. Since they are designed to treat a specific public health need and are intended for a small patient population, these medications frequently have a small market. They can be used to successfully treat a wide range of neurological, viral, chronic, chronically progressive, metabolic, hematologic, and oncological disorders. All of these life-threatening, degenerative, and crippling diseases lymphoma, glioma, leukemia, cystic fibrosis, ovarian cancer, immunologic, multiple myeloma, and renal cell carcinoma require specific treatment options that are effective for their individual symptoms. This element is anticipated to fuel the orphan drug market's expansion.

Governments from all around the world have implemented a range of incentives and regulations to encourage the development of orphan drugs. These consist of heightened market exclusivity, tax benefits, research subsidies, and expedited regulatory processes. These incentives have encouraged pharmaceutical companies to work on developing orphan medications. This element is anticipated to fuel the orphan drug market's expansion.

The advancement of diagnostic techniques and genetic studies has increased our understanding of rare diseases. This made it possible to identify specific molecular targets and pathways that orphan medicines can target, increasing the likelihood of successful drug development. This element is anticipated to fuel the orphan drug market's expansion.

Patient advocacy groups are crucial for advocating research funding, informing the public about rare diseases, and promoting the development of orphan drugs. Their campaigns have raised awareness of these diseases and boosted public and governmental support for the development of orphan medications. This element is anticipated to fuel the orphan drug market's expansion.

Orphan Drugs Market Share Analysis
One of the main producers of orphan drugs worldwide, Bristol-Myers Squibb has a market share of about 10%. Roche and Novartis are two more top producers.

Over 40% of sales are made in North America, which is the largest market, followed by Asia-Pacific. The big patient population, the presence of significant market players, and the tremendous investment in orphan medicines have all led to North America's strong market share and the development of sophisticated products.

Oncology is the largest sector by type, accounting for more than 60% of the market.

Regarding applicability, the adult market accounts for about 40% of the market.

SIMILAR REPORT

https://reports.valuates.com/market-reports/ALLI-Auto-4Z380/rheumatoid-arthritis-drugs

https://reports.valuates.com/market-reports/QYRE-Auto-4R2862/covid-19-impact-on-signifor-drugs

https://reports.valuates.com/market-reports/QYRE-Auto-34F7094/global-iv-and-oral-iron-drugs

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Twitter - https://twitter.com/valuatesreports

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Orphan Drugs Market Research Report 2023 here

News-ID: 3240120 • Views:

More Releases from Valuates Reports

Ultrasonic Cleaning Equipment Market Set to Surge - Key Insights You Must Know
Ultrasonic Cleaning Equipment Market Size The global market for Ultrasonic Cleaning Equipment was valued at US$ 2641 million in the year 2024 and is projected to reach a revised size of US$ 3349 million by 2031, growing at a CAGR of 3.5% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-10B11373/Global_Ultrasonic_Cleaning_Equipment_Market_Research_Report_2022 The implementation of patient protection acts and affordable treatment policies across the globe has intensified the demand for effective medical care equipment, in
Ultrasound Gel Market Set to Surge - Key Insights You Must Know
Ultrasound Gel Market Size The global market for Ultrasound Gel was estimated to be worth US$ 25.9 million in 2024 and is forecast to a readjusted size of US$ 29.3 million by 2031 with a CAGR of 1.8% during the forecast period 2025-2031. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1160/Global_Ultrasound_Gel_Market_Insights_and_Forecast_to_2028 North America is the largest Ultrasound Gel market with about 34% market share. Europe is follower, accounting for about 25% market share. The key players are Sonotech,
High and Ultra High Molecular Weight Polyethylene Market Set to Surge - Key Insi …
High and Ultra High Molecular Weight Polyethylene Market Size The global market for High and Ultra High Molecular Weight Polyethylene was valued at US$ 1017 million in the year 2024 and is projected to reach a revised size of US$ 1351 million by 2031, growing at a CAGR of 4.2% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-16J9911/Global_High_and_Ultra_High_Molecular_Weight_Polyethylene_Market_Insights_Forecast_to_2028 Global core manufactures of ultra-high molecular weight polyethylene (UHMWPE) include Celanese, Braskem, KPIC, Shanghai Lianle,
Logistics Management and Tracking Software Market Set to Surge - Key Insights Yo …
Logistics Management and Tracking Software Market Logistics Management and Tracking Software refers to specialized software solutions designed to streamline and optimize the management of transportation, inventory, warehousing, and other logistical operations within supply chains. This software provides comprehensive tools and functionalities to effectively plan, execute, and monitor the flow of goods and materials from suppliers to customers. Key features typically include order management, route optimization, warehouse management, inventory tracking, and real-time

All 5 Releases


More Releases for Orphan

Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031. Get Free Access to
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry …
Market Overview: According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028 Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the